Mall Volker, Heinen Florian, Siebel Andrea, Bertram Christoph, Hafkemeyer Ulrich, Wissel Jörg, Berweck Steffen, Haverkamp Fritz, Nass Günter, Döderlein Leo, Breitbach-Faller Nico, Schulte-Mattler Wilhelm, Korinthenberg Rudolf
Children's University Hospital, Freiburg University, Germany.
Dev Med Child Neurol. 2006 Jan;48(1):10-3. doi: 10.1017/S0012162206000041.
Adductor spasticity in children with cerebral palsy (CP) impairs motor function and development. In a placebo-controlled, double-blind, randomized multicentre study, we evaluated the effects of botulinum toxin A(BTX-A) in 61 children (37 males, 24 females; mean age 6 years 1 month [SD 3y 1mo]) with CP (leg-dominated tetraparesis, n=39; tetraparesis, n=22; GMFCS level I, n=3; II, n=6; III, n=17; IV, n=29; V, n=6). Four weeks after treatment, a significant superiority of BTX-A was observed in the primary outcome measure (knee-knee distance 'fast catch', p=0.002), the Ashworth scale (p=0.001), and the Goal Attainment Scale (p=0.037).
脑性瘫痪（CP）患儿的内收肌痉挛会损害运动功能和发育。在一项安慰剂对照、双盲、随机多中心研究中，我们评估了A型肉毒毒素（BTX-A）对61例CP患儿（男37例，女24例；平均年龄6岁1个月[标准差3岁1个月]）的疗效，这些患儿的CP类型为：以腿部为主的四肢轻瘫，n = 39；四肢轻瘫，n = 22；粗大运动功能分级系统（GMFCS）I级，n = 3；II级，n = 6；III级，n = 17；IV级，n = 29；V级，n = 6。治疗四周后，在主要结局指标（膝-膝距离“快速捕捉”，p = 0.002）、Ashworth量表（p = 0.001）和目标达成量表（p = 0.037）方面，观察到BTX-A具有显著优势。
